{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:46:15Z","timestamp":1790109975785,"version":"4.0.1"},"reference-count":20,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Prolactinomas are the most common functional pituitary tumor and are typically managed with dopamine agonists such as bromocriptine or cabergoline. Although these agents are generally well tolerated and effective in reducing prolactin levels and often tumor size, they have been implicated in rare but serious fibrotic complications, including interstitial lung disease (ILD). We describe a 65-year-old man with a longstanding prolactinoma who received cumulative high-dose bromocriptine and cabergoline therapy over several decades. Despite initial tumor shrinkage and partial biochemical control of hyperprolactinemia with dopamine agonists, stereotactic radiosurgery, and transsphenoidal surgery, the patient developed progressive exertional dyspnea and cough, accompanied by imaging and histopathological findings consistent with \u201cusual interstitial pneumonia\u201d (UIP). Autoimmune and environmental causes were largely excluded, suggesting a drug-induced etiology.<\/jats:p>\n               <jats:p>Following discontinuation of cabergoline, the patient has been on continued surveillance of his prolactin levels and tumor status, with symptomatic treatment of his UIP.<\/jats:p>\n               <jats:p>This case underscores the potential for dopamine agonist\u2013associated ILD, even in patients with prolactinomas who generally receive lower weekly doses than those used in Parkinson\u2019s and related diseases. Early recognition of respiratory symptoms, pulmonary function, and radiological investigations are indicated in selected symptomatic cases.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf067","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T09:26:53Z","timestamp":1744709213000},"source":"Crossref","is-referenced-by-count":1,"title":["Pulmonary Fibrosis in a Patient With a Prolactinoma on Dopamine Agonists: Coincidence or Consequence"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6893-2211","authenticated-orcid":false,"given":"Ravi","family":"Shah","sequence":"first","affiliation":[{"name":"Department of Endocrinology, PGIMER , Chandigarh 160012 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1457-8589","authenticated-orcid":false,"given":"Amanjit","family":"Bal","sequence":"additional","affiliation":[{"name":"Department of Histopathology, PGIMER , Chandigarh 160012 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5110-334X","authenticated-orcid":false,"given":"Durairaj","family":"Arjunan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, PGIMER , Chandigarh 160012 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1980-430X","authenticated-orcid":false,"given":"Jayaditya","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, PGIMER , Chandigarh 160012 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-6186","authenticated-orcid":false,"given":"Ashley B","family":"Grossman","sequence":"additional","affiliation":[{"name":"Green Templeton College, University of Oxford , Oxford OX1 2JD ,","place":["UK"]},{"name":"Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London , London E1 4NS ,","place":["UK"]},{"name":"NET Unit, ENETS Centre of Excellence, Royal Free Hospital , London NW3 2QG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5415-1611","authenticated-orcid":false,"given":"Pinaki","family":"Dutta","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, PGIMER , Chandigarh 160012 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"issue":"2","key":"2025041509362281800_luaf067-B1","doi-asserted-by":"crossref","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2025041509362281800_luaf067-B2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025041509362281800_luaf067-B3","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"19","key":"2025041509362281800_luaf067-B4","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/jama.2024.3669","article-title":"Interstitial lung disease: a review","volume":"331","author":"Maher","year":"2024","journal-title":"JAMA"},{"issue":"10","key":"2025041509362281800_luaf067-B5","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"key":"2025041509362281800_luaf067-B6","doi-asserted-by":"crossref","DOI":"10.31579\/2640-1045\/038","article-title":"Impulse control disorder in a patient with invasive prolactinoma on dopamine agonist therapy: a case report","author":"Dutta","year":"2019","journal-title":"J Endocrinol Disord"},{"issue":"1","key":"2025041509362281800_luaf067-B7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ando.2020.12.008","article-title":"The risks of medical treatment of prolactinoma","volume":"82","author":"Castinetti","year":"2021","journal-title":"Ann Endocrinol (Paris)"},{"issue":"1","key":"2025041509362281800_luaf067-B8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mds.22385","article-title":"Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists","volume":"24","author":"Andersohn","year":"2009","journal-title":"Mov Disord"},{"issue":"1","key":"2025041509362281800_luaf067-B9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"issue":"12","key":"2025041509362281800_luaf067-B10","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2174\/156802608785161457","article-title":"Receptor-binding and pharmacokinetic properties of dopaminergic agonists","volume":"8","author":"Kvernmo","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"2025041509362281800_luaf067-B11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3389\/fphar.2017.00492","article-title":"Pulmonary artery occlusion and mediastinal fibrosis in a patient on dopamine agonist treatment for hyperprolactinemia","volume":"8","author":"Su","year":"2017","journal-title":"Front Pharmacol"},{"issue":"4","key":"2025041509362281800_luaf067-B12","first-page":"380","article-title":"Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline","volume":"74","author":"Soyluk","year":"2023","journal-title":"Endokrynol Pol"},{"issue":"1","key":"2025041509362281800_luaf067-B13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2174\/1874306400903010090","article-title":"Pleuropulmonary toxicity of another anti-Parkinson's drug: cabergoline","volume":"3","author":"Belmonte","year":"2009","journal-title":"Open Respir Med J"},{"issue":"8","key":"2025041509362281800_luaf067-B14","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/archneur.62.8.1290","article-title":"Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson disease","volume":"62","author":"Tintner","year":"2005","journal-title":"Arch Neurol"},{"issue":"10","key":"2025041509362281800_luaf067-B15","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/archinte.1988.00380100089019","article-title":"Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease","volume":"148","author":"McElvaney","year":"1988","journal-title":"Arch Intern Med"},{"issue":"20","key":"2025041509362281800_luaf067-B16","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1158\/0008-5472.CAN-18-3064","article-title":"Prolactin promotes fibrosis and pancreatic cancer progression","volume":"79","author":"Tandon","year":"2019","journal-title":"Cancer Res"},{"issue":"5","key":"2025041509362281800_luaf067-B17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/00325481.2024.2373683","article-title":"Meta-analysis of the association between sex hormones and pulmonary fibrosis","volume":"136","author":"Chen","year":"2024","journal-title":"Postgrad Med"},{"key":"2025041509362281800_luaf067-B18","doi-asserted-by":"crossref","first-page":"120918","DOI":"10.1016\/j.lfs.2022.120918","article-title":"Dopamine receptor 3: a mystery at the heart of cardiac fibrosis","volume":"308","author":"Byrne","year":"2022","journal-title":"Life Sci"},{"key":"2025041509362281800_luaf067-B19","doi-asserted-by":"crossref","first-page":"b381","DOI":"10.1136\/bmj.b381","article-title":"Dopamine agonists and hyperprolactinaemia","volume":"338","author":"Martin","year":"2009","journal-title":"BMJ"},{"issue":"7","key":"2025041509362281800_luaf067-B20","first-page":"CD009718","article-title":"Dopamine agonists for idiopathic hyperprolactinaemia and prolactinoma in adults","volume":"2018","author":"Nunes-Nogueira","year":"2018","journal-title":"Cochrane Database Syst Rev"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/5\/luaf067\/62928798\/luaf067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/5\/luaf067\/62928798\/luaf067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T09:36:49Z","timestamp":1744709809000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf067\/8113469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3,27]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf067","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,3,27]]},"article-number":"luaf067"}}